Genetics of antiepileptic drug resistance

Current Opinion in Neurology

Volumn 22, Issue 2, 2009, Pages 150-156

  Sisodiya, Sanjay M ^a   Marini, Carla ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiepileptic drugs; Chromosome; Epilepsy; Genetics; Resistance

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; EPITHELIAL SODIUM CHANNEL; ION CHANNEL; PHENYTOIN; RAPAMYCIN; STIRIPENTOL; NERVE PROTEIN; SODIUM CHANNEL; SODIUM CHANNEL, VOLTAGE GATED, TYPE I, ALPHA PROTEIN; SODIUM CHANNEL, VOLTAGE-GATED, TYPE I, ALPHA PROTEIN;

ANTIEPILEPTIC RESISTANCE; CHANNELOPATHY; CHROMOSOME REARRANGEMENT; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESISTANCE; EPILEPSY; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; INTRACTABLE EPILEPSY; MUTATIONAL ANALYSIS; NONHUMAN; PHARMACOGENOMICS; POINT MUTATION; REVIEW; SEIZURE; TUBEROUS SCLEROSIS; DRUG HYPERSENSITIVITY; GENE REARRANGEMENT; GENETICS; HUMAN CHROMOSOME;

ANTICONVULSANTS; CHROMOSOMES, HUMAN; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; EPILEPSY; GENE REARRANGEMENT; HUMANS; NERVE TISSUE PROTEINS; SODIUM CHANNELS;

EID: 68849122859     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32832923ec     Document Type: Review

References (41)

1. Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007; 48:2224-2233.
2. Mulley JC, Scheffer IE, Petrou S, et al. SCN1A mutations and epilepsy. Hum Mutat 2005; 25:535-542.
3. Marini C, Mei D, Temudo T, et al. Idiopathic epilepsies with seizures pre cipitated by fever and SCN1A abnormalities. Epilepsia 2007; 48:1678-1685.
4. Depienne C, Trouillard O, Saint-Martin C, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet 2008 [Epub ahead of print].
5. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9:1142-1149; Erratum in: Nat Neurosci 2007; 10:134.
6. Ogiwara I, Miyamoto H, Morita N, et al. Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007; 27:5903-5914.
7. Kassaï B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 2008; 49:343-348.
8. Fisher JL. The anticonvulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 2008; 56:190-197.
9. Quilichini P, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug enhances the duration of opening of GABAA receptor channels. Epilepsia 2006; 47:704-716.
10. Rusconi R, Scalmani P, Cassulini RR, et al. Modulatory proteins can rescue a trafficking defective epileptogenic Nav1.1 Na+ channel mutant. J Neurosci 2007; 27:11037-11046.
11. George AL Jr. Inherited disorders of voltage-gated sodium channels. J Clin Invest 2005; 115:1990-1999.
12. Kumakura A, Ito M, Hata D, et al. Novel de novo splice-site mutation of SCN1A in a patient with partial epilepsy with febrile seizures plus. Brain Dev 2009; 31:179-182.
13. Okumura A, Kurahashi H, Hirose S, et al. Focal epilepsy resulting from a de novo SCN1A mutation. Neuropediatrics 2007; 38:253-256.
14. Martin MS, Tang B, Papale LA, et al. The voltage-gated sodium channel Scn8a is a genetic modifier of severe myoclonic epilepsy of infancy. Hum Mol Genet 2007; 16:2892-2899.
15. Ohmori I, Ouchida M, Miki T, et al. A CACNB4 mutation shows that altered Ca(v)2.1 function may be a genetic modifier of severe myoclonic epilepsy in infancy. Neurobiol Dis 2008; 32:349-354.
16. Glasscock E, Qian J, Yoo JW, Noebels JL. Masking epilepsy by combining two epilepsy genes. Nat Neurosci 2007; 10:1554-1558.
17. Zimprich F, Stogmann E, Bonelli S, et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 2008; 49:1108-1109.
18. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the antiepileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 2005; 102:5507-5512.
19. Abe T, Seo T, Ishitsu T, et al. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol 2008; 66:304-307.
20. Kwan P, Poon WS, Ng HK, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 2008; 18:989-998.
21. Scheffer IE, Harkin LA, Grinton BE, et al. Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain 2007; 130 (Pt 1):100-109.
22. Xu R, Thomas EA, Gazina EV, et al. Generalized epilepsy with febrile seizures plus-associated sodium channel beta1 subunit mutations severely reduce beta subunit-mediated modulation of sodium channel function. Neuroscience 2007; 148:164-174.
23. Bahi-Buisson N, Nectoux J, Rosas-Vargas H, et al. Key clinical features to identify girls with CDKL5 mutations. Brain 2008; 131 (Pt 10):2647-2661.
24. Elia M, Falco M, Ferri R, et al. CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology 2008; 71:997-999.
25. Bahi-Buisson N, Poirier K, Boddaert N, et al. Refinement of cortical dysgeneses spectrum associated with TUBA1A mutations. J Med Genet 2008; 45:647-653.
26. Saitsu H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet 2008; 40:782-788.
27. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008; 63:444-453.
28. Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2+// mouse model of tuberous sclerosis. Nat Med 2008; 14:843-848.
29. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59:490-498.
30. Roulet-Perez E, Ballhausen D, Bonafé L, et al. Glut-1 deficiency syndrome masquerading asidiopathicgeneralizedepilepsy.Epilepsia2008;49:1955- 1958.
31. Wang JW, Kurahashi H, Ishii A, et al. Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia 2008; 49:1528-1534.
32. Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008; 455:232-236.
33. Weiss LA, Shen Y, Korn JM, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008; 358:667-675.
34. Mefford HC, Clauin S, Sharp AJ, et al. Recurrent reciprocal genomic re arrangements of 17q12 are associated with renal disease, diabetes, and epilepsy. Am J Hum Genet 2007; 81:1057-1069.
35. Striano P, Mancardi MM, Biancheri R, et al. Brain MRI ?ndings in severe myoclonic epilepsy in infancy and genotype-phenotype correlations. Epilepsia 2007; 48:1092-1096.
36. Sharp AJ, Mefford HC, Li K, et al. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat Genet 2008; 40:322-328.
37. Kossoff EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009; 50:304-317.
38. Garriga-Canut M, Schoenike B, Qazi R, et al. 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci 2006; 9:1382-1387.
39. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348:1442-1448.
40. Bournissen FG, Moretti ME, Juurlink DJ, et al. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia [Epub ahead of print].
41. Tate SK, Sisodiya SM. Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opin Pharmacother 2007; 8:1441-1449.